WallStSmart

Conduit Pharmaceuticals Inc. (CDT)vsModerna Inc (MRNA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

CDT leads profitability with a 0.0% profit margin vs -141.4%. CDT earns a higher WallStSmart Score of 26/100 (F).

CDT

Avoid

26

out of 100

Grade: F

Growth: 4.3Profit: 3.5Value: 5.0Quality: 6.5
Piotroski: 4/9Altman Z: 1.84

MRNA

Avoid

21

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 6.7Quality: 7.5
Piotroski: 3/9Altman Z: 2.09
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CDT.

MRNAUndervalued (+70.0%)

Margin of Safety

+70.0%

Fair Value

$134.97

Current Price

$143.97

$9.00 discount

UndervaluedFair: $134.97Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CDT1 strengths · Avg: 10.0/10
Price/BookValuation
0.0x10/10

Reasonable price relative to book value

MRNA2 strengths · Avg: 9.0/10
Market CapQuality
$56.02B9/10

Large-cap with strong market position

Debt/EquityHealth
0.199/10

Conservative balance sheet, low leverage

Areas to Watch

CDT4 concerns · Avg: 3.8/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Altman Z-ScoreHealth
1.844/10

Grey zone — moderate risk

Market CapQuality
$3.42M3/10

Smaller company, higher risk/reward

MRNA4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Revenue GrowthGrowth
2.1%4/10

2.1% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-46.6%2/10

ROE of -46.6% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : CDT

The strongest argument for CDT centers on Price/Book.

Bull Case : MRNA

The strongest argument for MRNA centers on Market Cap, Debt/Equity.

Bear Case : CDT

The primary concerns for CDT are Revenue Growth, EPS Growth, Altman Z-Score.

Bear Case : MRNA

The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

CDT profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.

CDT carries more volatility with a beta of 1.45 — expect wider price swings.

MRNA is growing revenue faster at 2.1% — sustainability is the question.

CDT generates stronger free cash flow (2M), providing more financial flexibility.

Bottom Line

CDT scores higher overall (26/100 vs 21/100). MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Conduit Pharmaceuticals Inc.

HEALTHCARE · BIOTECHNOLOGY · USA

Conduit Pharmaceuticals Inc. (CDT) is a clinical-stage biopharmaceutical company focused on creating innovative therapies for oncology and rare diseases, targeting significant unmet medical needs. Utilizing its proprietary drug delivery technology, Conduit aims to improve the efficacy and safety of existing treatments, thereby enhancing patient outcomes and reducing adverse effects. Supported by a seasoned management team and strategic collaborations, the company is well-positioned to advance its pipeline of transformative products, with the potential to significantly influence the healthcare landscape.

Visit Website →

Moderna Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.

Want to dig deeper into these stocks?